CN101704872A - 23-羟基白桦酸衍生物、其制备方法及应用 - Google Patents
23-羟基白桦酸衍生物、其制备方法及应用 Download PDFInfo
- Publication number
- CN101704872A CN101704872A CN200910186536A CN200910186536A CN101704872A CN 101704872 A CN101704872 A CN 101704872A CN 200910186536 A CN200910186536 A CN 200910186536A CN 200910186536 A CN200910186536 A CN 200910186536A CN 101704872 A CN101704872 A CN 101704872A
- Authority
- CN
- China
- Prior art keywords
- acid
- hydroxyl radical
- zhangnan
- radical white
- white birck
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- HXWLKAXCQLXHML-WGOZWDAUSA-N 23-Hydroxybetulinic acid Chemical class C1C[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C HXWLKAXCQLXHML-WGOZWDAUSA-N 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 82
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 13
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 12
- 229940124321 AIDS medicine Drugs 0.000 claims abstract description 7
- 239000002253 acid Substances 0.000 claims description 82
- 244000274847 Betula papyrifera Species 0.000 claims description 28
- 235000009113 Betula papyrifera Nutrition 0.000 claims description 28
- 235000009109 Betula pendula Nutrition 0.000 claims description 28
- 235000010928 Betula populifolia Nutrition 0.000 claims description 28
- 235000002992 Betula pubescens Nutrition 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000003937 drug carrier Substances 0.000 claims description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 9
- 235000002639 sodium chloride Nutrition 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 8
- 239000012044 organic layer Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000012047 saturated solution Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 229940126214 compound 3 Drugs 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000470 constituent Substances 0.000 claims 1
- 239000012059 conventional drug carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 36
- 210000004881 tumor cell Anatomy 0.000 abstract description 27
- 239000013641 positive control Substances 0.000 abstract description 12
- 201000001441 melanoma Diseases 0.000 abstract description 7
- 238000011160 research Methods 0.000 abstract description 7
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 5
- 230000006907 apoptotic process Effects 0.000 abstract description 5
- 230000012010 growth Effects 0.000 abstract description 4
- 208000032839 leukemia Diseases 0.000 abstract description 4
- 201000005202 lung cancer Diseases 0.000 abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 abstract description 4
- 206010060862 Prostate cancer Diseases 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 238000013415 human tumor xenograft model Methods 0.000 abstract description 3
- 206010018338 Glioma Diseases 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 29
- 239000003814 drug Substances 0.000 description 16
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 241000700605 Viruses Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 231100001274 therapeutic index Toxicity 0.000 description 11
- 208000030507 AIDS Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 239000003513 alkali Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 7
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 6
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 6
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZGDKVKUWTCGYOA-URGPHPNLSA-N [4-[4-[(z)-c-(4-bromophenyl)-n-ethoxycarbonimidoyl]piperidin-1-yl]-4-methylpiperidin-1-yl]-(2,4-dimethyl-1-oxidopyridin-1-ium-3-yl)methanone Chemical compound C=1C=C(Br)C=CC=1C(=N/OCC)\C(CC1)CCN1C(CC1)(C)CCN1C(=O)C1=C(C)C=C[N+]([O-])=C1C ZGDKVKUWTCGYOA-URGPHPNLSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 6
- 230000000452 restraining effect Effects 0.000 description 6
- 210000000582 semen Anatomy 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 208000005017 glioblastoma Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- HXWLKAXCQLXHML-UHFFFAOYSA-N Anemosapogenin Natural products C1CC(O)C(C)(CO)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C HXWLKAXCQLXHML-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000206469 Pulsatilla Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000798 anti-retroviral effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- HXWLKAXCQLXHML-QUEFYMJYSA-N 23-Hydroxybetulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)CC4)CC3)CC1)CC2 HXWLKAXCQLXHML-QUEFYMJYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 230000009876 antimalignant effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- UECIPBUIMXSXEI-BNSVOVDNSA-N eremomycin Chemical compound O([C@@H]1C2=CC=C(C=C2)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(N)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 UECIPBUIMXSXEI-BNSVOVDNSA-N 0.000 description 1
- UECIPBUIMXSXEI-UHFFFAOYSA-N eremomycin Natural products C=1C2=CC=C(O)C=1C1=C(O)C=C(O)C=C1C(C(O)=O)NC(=O)C1NC(=O)C2NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC(C=3OC4C(C(O)C(O)C(CO)O4)OC4OC(C)C(O)C(C)(N)C4)=CC2=CC=3OC(C=C2)=CC=C2C1OC1CC(C)(N)C(O)C(C)O1 UECIPBUIMXSXEI-UHFFFAOYSA-N 0.000 description 1
- 108010013356 eremomycin Proteins 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001972 liquid chromatography-electrospray ionisation mass spectrometry Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- -1 lupane glycosides Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 150000002966 pentacyclic triterpenoids Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Description
人肿瘤细胞株 | 细胞类型 | zhangnan-5EC50(uM) | zhangnan-7EC50(uM) | zhangnan-8EC50(uM) |
LnCAP | 前列腺 | 0.69 | 15.6 | 7.8 |
D145 | 前列腺 | 0.85 | 14.8 | 8.4 |
PC3 | 前列腺 | 0.91 | 16.2 | 8.9 |
HCT-116 | 结肠 | 0.09 | 15.1 | 7.8 |
Widr | 结肠 | 0.28 | 14.8 | 8.1 |
HT29 | 结肠 | 0.47 | 13.9 | 8.9 |
LoVo | 结肠 | 0.15 | 15.2 | 9.6 |
CCL-225 | 结肠 | 0.23 | 16.1 | 8.6 |
CCL-247 | 结肠 | 0.52 | 15.6 | 8.2 |
NCI-H23 | 肺 | 0.32 | 12.8 | 6.7 |
A549 | 肺 | 0.54 | 13.1 | 6.9 |
MDA-MB-231 | 乳腺 | 0.47 | 17.5 | 7.2 |
MDA-MB-435 | 乳腺 | 0.55 | 19.3 | 7.9 |
AU-565 | 乳腺 | 0.59 | 18.2 | 6.8 |
BT-549 | 乳腺 | 0.67 | 17.4 | 7.4 |
人肿瘤细胞株 | 细胞类型 | zhangnan-5EC50(uM) | zhangnan-7EC50(uM) | zhangnan-8EC50(uM) |
MCF-7 | 乳腺 | 0.58 | 16.9 | 7.8 |
Caki-1 | 肾 | 0.98 | 20.1 | 9.2 |
ACHN | 肾 | 1.2 | 18.3 | 8.9 |
786-O | 肾 | 3.1 | 16.8 | 8.1 |
SN12C | 肾 | 1.3 | 17.5 | 7.6 |
SKOV3 | 卵巢 | 1.5 | 16.9 | 6.9 |
IGROV1 | 卵巢 | 2.1 | 17.4 | 7.2 |
Mid PaCa-2 | 胰腺 | 0.93 | 18.9 | 9.4 |
U-251 | 恶性胶质瘤 | 0.089 | 17.8 | 5.6 |
SK-MEL-5 | 皮肤(黑色 | 0.093 | 18.5 | 4.9 |
G-361 | 皮肤(黑色 | 0.087 | 19.3 | 5.3 |
MCF-10a | 正常乳腺上皮细胞 | >30 | >30 | >30 |
SGC-7901 | 胃 | 0.89 | 18.5 | 8.9 |
EC109 | 食管 | 0.78 | 17.9 | 9.5 |
CNE-2Z | 鼻咽 | 1.3 | 19.2 | 10.2 |
Raji | 淋巴瘤 | 0.098 | 20.5 | 6.9 |
Jurkat | 白血病T细 | 0.14 | 21.3 | 7.1 |
人肿瘤细胞株 | 细胞类型 | zhangnan-5EC50(uM) | zhangnan-7EC50(uM) | zhangnan-8EC50(uM) |
MEF | 正常小鼠成纤维细胞 | >30 | >30 | >30 |
药代动力学参数 | 均数+/-标准差 |
T1/2(hour) | 11.5+/-0.8 |
Tmax(min) | 85+/-7 |
Cmax(uM) | 65+/-9 |
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101865366A CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
US13/511,399 US20120302530A1 (en) | 2009-11-23 | 2010-05-13 | 23-hydroxy-betulinic acid derivatives, preparation methods and uses thereof |
PCT/CN2010/072740 WO2011060634A1 (zh) | 2009-11-23 | 2010-05-13 | 23-羟基白桦酸衍生物、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101865366A CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101704872A true CN101704872A (zh) | 2010-05-12 |
CN101704872B CN101704872B (zh) | 2012-06-27 |
Family
ID=42375131
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101865366A Expired - Fee Related CN101704872B (zh) | 2009-11-23 | 2009-11-23 | 23-羟基白桦酸衍生物、其制备方法及应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20120302530A1 (zh) |
CN (1) | CN101704872B (zh) |
WO (1) | WO2011060634A1 (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101961339A (zh) * | 2010-10-21 | 2011-02-02 | 中国药科大学 | 23-hba在制备降低阿霉素所致心脏毒性的药物中的应用 |
WO2011060634A1 (zh) * | 2009-11-23 | 2011-05-26 | 苏州麦迪仙医药科技有限公司 | 23-羟基白桦酸衍生物、其制备方法及应用 |
CN113173964A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物及其制备方法 |
CN113173963A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物、制备方法及其应用 |
CN113173965A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦酸衍生物及其制备方法 |
CN114908645A (zh) * | 2022-04-25 | 2022-08-16 | 杭州傲翔控股有限公司 | 一种机场钢筋混凝土排水沟浇筑施工方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111417384A (zh) | 2017-09-14 | 2020-07-14 | 菲尼克斯生物技术公司 | 用于治疗神经系统病况的方法和改进的神经保护性组合物 |
KR20210107904A (ko) | 2017-09-14 | 2021-09-01 | 피닉스 바이오테크놀러지 인코포레이티드. | 바이러스 감염 치료를 위한 조성물 |
US11469553B2 (en) | 2020-01-27 | 2022-10-11 | Fci Usa Llc | High speed connector |
SG11202105728YA (en) | 2020-03-31 | 2021-11-29 | Phoenix Biotechnology Inc | Method and compositions for treating coronavirus infection |
EP4295854A3 (en) | 2020-03-31 | 2024-04-03 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
CN115232187B (zh) * | 2022-08-10 | 2024-04-12 | 江西省科学院应用化学研究所 | 一种从龙脑樟中提取7β-羟基白桦脂酸的方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100551375C (zh) * | 2003-09-02 | 2009-10-21 | 叶文才 | 23-羟基白桦酸在制备治疗或预防脑神经胶质瘤药物中的应用 |
CN104844678B (zh) * | 2007-05-11 | 2018-02-09 | 香港科技大学 | 具有神经保护和增强记忆活性的受体调节剂 |
CN101428071B (zh) * | 2007-11-06 | 2012-02-22 | 天津天士力制药股份有限公司 | 一种白头翁的有效组分及其制备方法与用途 |
CN101704872B (zh) * | 2009-11-23 | 2012-06-27 | 张南 | 23-羟基白桦酸衍生物、其制备方法及应用 |
-
2009
- 2009-11-23 CN CN2009101865366A patent/CN101704872B/zh not_active Expired - Fee Related
-
2010
- 2010-05-13 WO PCT/CN2010/072740 patent/WO2011060634A1/zh active Application Filing
- 2010-05-13 US US13/511,399 patent/US20120302530A1/en not_active Abandoned
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011060634A1 (zh) * | 2009-11-23 | 2011-05-26 | 苏州麦迪仙医药科技有限公司 | 23-羟基白桦酸衍生物、其制备方法及应用 |
CN101961339A (zh) * | 2010-10-21 | 2011-02-02 | 中国药科大学 | 23-hba在制备降低阿霉素所致心脏毒性的药物中的应用 |
CN113173964A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物及其制备方法 |
CN113173963A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦醇衍生物、制备方法及其应用 |
CN113173965A (zh) * | 2021-04-14 | 2021-07-27 | 籍建亚 | 一种抗肿瘤的白桦酸衍生物及其制备方法 |
CN114908645A (zh) * | 2022-04-25 | 2022-08-16 | 杭州傲翔控股有限公司 | 一种机场钢筋混凝土排水沟浇筑施工方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101704872B (zh) | 2012-06-27 |
US20120302530A1 (en) | 2012-11-29 |
WO2011060634A1 (zh) | 2011-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101704872B (zh) | 23-羟基白桦酸衍生物、其制备方法及应用 | |
Zhang et al. | Betulinic acid and the pharmacological effects of tumor suppression | |
Liu et al. | Synthesis and in vitro antitumor activity of novel scopoletin derivatives | |
Kommera et al. | Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity | |
Popović-Djordjević et al. | Natural products and synthetic analogues against HIV: A perspective to develop new potential anti-HIV drugs | |
Cui et al. | Triterpenoid saponins from the genus Camellia: Structures, biological activities, and molecular simulation for structure–activity relationship | |
Peng et al. | Antitumor activity of C-21 steroidal glycosides from Cynanchum auriculatum Royle ex Wight | |
PT1068219E (pt) | Derivados acilados de betulina e de di-hidrobetulina, sua preparação e sua utilização | |
CN101878218A (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
Xu et al. | Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol | |
Ni et al. | Discovery, synthesis of novel fusidic acid derivatives possessed amino-terminal groups at the 3-hydroxyl position with anticancer activity | |
CN107163026A (zh) | 吡啶胺基嘧啶衍生物的盐及其制备方法和应用 | |
Jo et al. | Ginsenoside 20 (S)-protopanaxadiol induces cell death in human endometrial cancer cells via apoptosis | |
Sombut et al. | Synthesis of 14-deoxy-11, 12-didehydroandrographolide analogues as potential cytotoxic agents for cholangiocarcinoma | |
CN104586873B (zh) | 木蝴蝶苷a在制备治疗癌症药物中的应用 | |
WO2008148269A1 (fr) | Médicament anti-tumoral contenant des dérivés d'acide bétulinique | |
CN102030800B (zh) | 杉松三萜类化合物及其提取分离与应用 | |
CN102552370A (zh) | 两种广谱抗肿瘤药物及其制备方法 | |
CN101830847B (zh) | 抗癌用化合物及制备方法 | |
CN105859823A (zh) | 救必应酸酯类衍生物在制备抗肿瘤药物中的应用 | |
Kang et al. | Discovery of a novel water-soluble, rapid-release triptolide prodrug with improved drug-like properties and high efficacy in human acute myeloid leukemia | |
CN102030813B (zh) | 一种具有高效抗癌活性的黄姜盾叶新苷的制备方法及其用途 | |
US10959974B2 (en) | Ingenol compounds and use thereof in anti-HIV latency treatment | |
Long et al. | Inhibition of colon cancer cell growth by imidazole through activation of apoptotic pathway | |
CN102068452B (zh) | 一种具有抗病毒作用的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ZHONG RONG SUZHOU MAIDIXIAN PHARMACEUTICAL TECHNOL Owner name: ZHANG NAN Free format text: FORMER OWNER: SUZHOU MAIDIXIAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20110221 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 215125 ROOM 201-G, BUILDING A3, BIOLOGICAL NANOMETER PARK, NO. 218, XINGHU STREET, INDUSTRIAL PARK, SUZHOU CITY, JIANGSU PROVINCE TO: 210008 602, BUILDING 3, NO. 33, JINXIANGHE ROAD, XUANWU DISTRICT, NANJING CITY, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110221 Address after: Jinxiang River Road Xuanwu District of Nanjing Jiangsu province 210008 No. 33 building 3 602 Applicant after: Zhang Nan Co-applicant after: Zhong Rong Co-applicant after: Suzhou Maidixian Medical Technology Co.,Ltd. Address before: Xinghu Street Industrial Park of Suzhou city in Jiangsu province 215125 No. 218 BioBAY A3 building room 201-G Applicant before: Suzhou Maidixian Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120627 Termination date: 20191123 |
|
CF01 | Termination of patent right due to non-payment of annual fee |